CClinicalTrials.gg
CompletedNCT04045275Updated Feb 26, 2020

Feasibility of a Mobile App on Sleep

An interventional study of Calm in Sleep Disturbance, sponsored by Arizona State University. Completed at 1 site in United States. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2020-02-26.

Sponsored by Arizona State University · Not applicable, Interventional, and Treatment

Phase
Not applicable
Study type
Interventional
Enrollment
285
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

This study investigates the feasibility and effects of a mindfulness meditation mobile application on sleep for individuals reporting sleep disturbances.

Read the detailed description

The purpose of this study is to investigate the effects of a mindfulness meditation mobile application on sleep in individuals reporting sleep disturbances.

The investigator's guiding hypothesis is that the combined elements of a consumer-based mobile meditation app, Calm (e.g., daily mindfulness meditation, sleep stories and behavioral components), will be feasible, accepted and associated with sustained improvement in sleep among individuals who self-identify as having sleep disturbances. Calm provides daily, 10-minute, guided meditations grounded in mindfulness-based stress reduction (MBSR) and Vipassana meditation. Uniquely, Calm also offers "Sleep Stories", developed using techniques from Cognitive Behavioral Therapy and Relaxation Technique.

This is a randomized control feasibility study with an intervention and waitlist control.

Aim 1: Examine the feasibility of using a consumer-based mindful meditation app for >10 mins/day over eight weeks for 100 adults who self-identify as sleep disturbed.

Aim 2: Explore the preliminary effects of Calm on sleep disturbance and emotional symptoms associated with sleep disturbance (i.e. stress, anxiety, depressive symptoms) as compared to those in a wait-list control group.

Recruitment: Participants will be recruited nationally via Internet-based strategies including social media (e.g. Facebook, Twitter, Instagram), social networking sites and email listservs. Recruitment flyers will be posted on social media websites. ResearchMatch.org will be also be utilized as a recruitment tool for this protocol.

Eligibility: Inclusion criteria are: (1) self-identify as sleep disturbed (i.e., score >10 on the Insomnia Severity Index), (2) >18 years of age, (3) English speaking, (4) willing to download the Calm app to their smartphone, and (5) have not practiced meditation more than 60 minutes a month in the past six months (6) willing to be randomized. Participants will report use of medication for sleep at baseline, mid-intervention and post-intervention and not excluded for medication.

Enrollment: Interested participants will complete a brief (5-10 minute) eligibility screener via Qualtrics. Participants will not be made know of sponsor name before randomization assignment to avoid disclosing the app that they will be using. Eligible participants will be asked to sign an electronic informed consent prior to the start of the intervention. After informed consents have been completed, participants (N=100) will be identified. Once eligible participants have been identified, they will be emailed instructions. Ineligible participants will be notified by email.

Tracking: Intervention participants (n=50) usage will be continuously tracked throughout the intervention by Calm.

Post-intervention: Post-intervention questionnaire will be emailed to intervention and control participants via a link from Qualtrics. All participants will have access to Calm after the 8-week study period, but will not be asked to meditate.

02

Conditions studied

  • Sleep Disturbance
03

In context

Dyssomnias

324 studies on the registry are indexed under Dyssomnias; 51 are open to participants now.

This study's enrollment of 285 is above the median of 60 across 251 interventional studies indexed under Dyssomnias.

Browse Dyssomnias studies →

Lead sponsor

Arizona State University is the lead sponsor of 234 studies on the registry; 41 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Inclusion criteria

  • self-identify as sleep disturbed (i.e., score >10 on the Insomnia Severity Index)
  • at least 18 years of age
  • English speaking
  • willing to download Clam app on their smartphone
  • willing to be randomized

Exclusion criteria

Exclusion Criteria:

  • have participated in more than 60 minutes of meditation/month within the past six months
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
285 participants (actual)

Study arms

  • Experimental
    Calm

    The intervention will occur across 8 weeks. During Week 1, it is suggested to intervention participants that they complete "7 days of Calm" meditation series (7 meditations, each approximately 10 minutes long, created to help users learn the basics of mindfulness meditations. For the remaining weeks (Week 2- Week 8) intervention participants will be asked to meditate for 10 minutes per day using any of the meditation sessions/features. Throughout the intervention, participants not completing 30 minutes of meditation per week will be sent reminders texts/emails.

    Behavioral: Calm

  • No intervention
    Control

    This group is a wait-list control group who will receive the intervention following the 8-week waiting period. Participants in this condition are instructed not to start meditating before the waiting period. After the 8-week waiting period, waitlist participants will receive the same intervention as described in the Calm Arm.

Interventions

  • BehavioralCalm

    Calm provides daily, 10-minute, guided meditations grounded in mindfulness-based stress reduction (MBSR) and Vipassana meditation. Calm also offers "Sleep Stories," developed using techniques from Cognitive Behavioral Therapy and Relaxation Technique. Clam also includes behavioral components to reinforce sustained practice.

06

What researchers measure

Primary outcomes

  1. Acceptability, as measured by participants' satisfaction with the content in the mindful meditation app

    Participants' satisfaction will be measured by participant responses to the item, "On a scale of 1-5 (1=did not enjoy at all, 5=very much enjoyed), how would you rate your overall enjoyment with using Calm (i.e., likeable, pleasurable)?" on an investigator-developed survey. Participants rate their satisfaction on a five-point scale, ranging from 1 (did not enjoy at all) to 5 (very much enjoyed).

    Time frame: Participant satisfaction is measured immediately after the the conclusion of the 8-week intervention.

  2. Acceptability, as measured by participants' perceptions of the appropriateness of the content in the mindful meditation app

    Participants' perceptions of appropriateness will be measured using six items on investigator-developed survey. Items inquire about participants' perceptions regarding the app's ease of use, aesthetics and graphics, and adequacy of the instruction (all rated on 1-5 scales, with higher ratings reflecting greater perceived appropriateness), and three items about the appropriateness of the duration of daily meditations, sleep meditations, and Sleep Stories (rated on a 1-4 scale, with higher ratings reflecting greater perceived appropriateness). Average scores will be reported for each item.

    Time frame: Participants' perceptions of appropriateness are measured immediately after the the conclusion of the 8-week intervention.

  3. Demand, as assessed by the percentage of participants who use the mindful meditation app for the 70% of the prescribed weekly minutes (≥ 70 minutes/week)

    The amount of time that participants use the app will be recorded by Calm (internally) and shared with Arizona State University.

    Time frame: Duration use app use is recorded continuously throughout the 8-week intervention.

  4. Demand, as assessed by the the comparative frequency of participants use of meditation, sleep meditation, and Sleep Stories

    The frequency of using individual app components will be recorded by Calm (internally) and shared with Arizona State University.

    Time frame: Frequency of use app use is recorded continuously throughout the 8-week intervention.

  5. Demand, as assessed by the the comparative duration of participants use of meditation, sleep meditation, and Sleep Stories

    The amount of time that participants use the app individual app components will be recorded by Calm (internally) and shared with Arizona State University.

    Time frame: Duration use app use is recorded continuously throughout the 8-week intervention.

  6. Preliminary effects of the mindfulness meditation app on sleep disturbance, as assessed by changes in participants' nightly sleep duration over the course of the 8-week intervention period

    Sleep duration will be calculated using participants' reports of the time they fell asleep at night, the time that they woke up in the morning, and the amount time spent awake after waking up during the night. These times are self-reported in a gold-standard daily sleep diary.

    Time frame: Sleep diaries are completed daily throughout the 8-week intervention. Each morning, participants report on the previous night's sleep. Participants submit their daily diary entries at the end of each week.

  7. Preliminary effects of the mindfulness meditation app on sleep disturbance, as assessed by changes in the amount of time required for participants' to fall asleep over the course of the 8-week intervention period

    The amount of time required to fall asleep will be measured by participants' self-reports in their daily sleep diaries.

    Time frame: Sleep diaries are completed daily throughout the 8-week intervention. Each morning, participants report on the previous night's sleep. Participants submit their daily diary entries at the end of each week.

  8. Preliminary effects of the mindfulness meditation app on sleep disturbance, as assessed by changes in the frequency of participants' nightly mid-sleep awakenings over the course of the 8-week intervention period

    The frequency of mid-sleep awakenings will be measured by participants' self-reports in their daily sleep diaries.

    Time frame: Sleep diaries are completed daily throughout the 8-week intervention. Each morning, participants report on the previous night's sleep. Participants submit their daily diary entries at the end of each week.

  9. Preliminary effects of the mindfulness meditation app on sleep disturbance, as assessed by changes in the amount of time spent awake after mid-sleep awakenings over the course of the 8-week intervention period

    The amount of time spent awake after mid-sleep awakenings will be measured by participants' self-reports in their daily sleep diaries.

    Time frame: Sleep diaries are completed daily throughout the 8-week intervention. Each morning, participants report on the previous night's sleep. Participants submit their daily diary entries at the end of each week.

  10. Preliminary effects of the mindfulness meditation app on sleep disturbance, as assessed by changes in participants rating of sleep quality over the course of the 8-week intervention period

    Sleep quality will be measured by participants' responses to the question, "How would you rate the quality of your sleep? (1= very poor and 5= very good)," which is included in participants' daily sleep diaries.

    Time frame: Sleep diaries are completed daily throughout the 8-week intervention. Each morning, participants report on the previous night's sleep. Participants submit their daily diary entries at the end of each week.

  11. Preliminary effects of the mindfulness meditation app on sleep disturbance, as assessed by changes in participants' pre- and post-intervention scores on the Cognitive and Somatic Arousal subscales of the Pre-Sleep Arousal Scale

    The Pre-Sleep Arousal Scale is a 16-item self-report questionnaire that measures arousal before sleep. Items describe symptoms of cognitive and somatic arousal. Using a five-point scale (1, not at all; 2, slightly: 3, moderately; 4, a lot; 5, extremely), participants rate extent to which they generally experience each symptom as they attempt to fall asleep. The Pre-Sleep Arousal Scale is comprised of two eight-item subscales, which assess Cognitive Somatic arousal. Subscale scores are determined by summing ratings from the included items. Possible scores on each subscale range from 8 to 40, with higher scores indicating greater pre-sleep arousal.

    Time frame: The Pre-Sleep Arousal Scale will be completed at immediately before (i.e., baseline) and immediately after the intervention

  12. Preliminary effects of the mindfulness meditation app on sleep fatigue, as assessed by changes in participants' pre- and post-intervention scores on the Fatigue Severity Scale

    The Fatigue Severity Scale is a nine-item self-report measure of fatigue and the extent to which fatigue interferes with daily living. Respondents rate the extent to which they agree with statements about their experience with fatigue during the past week. Items are scored on a seven-point scale ranging from 1 to 7 (1=strongly disagree, 7=strongly agree). Total scores range from 1 to 7, reflecting the mean rating of the items. Higher scores indicate greater fatigue.

    Time frame: The Fatigue Severity Scale will be completed at immediately before (i.e., baseline) and immediately after the intervention

  13. Preliminary effects of the mindfulness meditation app on sleepiness, as assessed by changes in participants' pre- and post-intervention scores on the Epworth Sleepiness Scale

    The Epworth Sleepiness Scale is an eight-item measure of daytime sleepiness. Respondents use a four-point scale to rate the likeliness that they would doze off or fall asleep in eight situations involving activities with low levels of stimulation, relative immobility, and relaxation, based on their usual way of life in recent times. Item ratings range from 0 to 3 (0=would never doze, 3=high chance of dozing). Items are summed to calculate a total score, ranging from 0 to 24, with higher scores indicating greater sleepiness.

    Time frame: The Epworth Sleepiness Scale will be completed at immediately before (i.e., baseline) and immediately after the intervention

Secondary outcomes

  1. Preliminary effects of the mindfulness meditation app on depression, as assessed by changes in participants' pre- and post-intervention scores on the Depression Anxiety Stress Scale-21 Items

    The Depression Anxiety Stress Scale-21 Items is a set of three seven-item self-report scales measuring depression, anxiety, and stress/tension. Respondents use a four-point scale, ranging from 0 to 3, to rate the extent to which symptoms of depression, anxiety, and stress apply to their experiences during the past week (0=did not apply to me at all, 3=applied to me very much, or most of the time). For each scale, ratings for the relevant items are summed, and sums for each scale are multiplied by two to allow for comparison with scores from the original the 42-item version of the Depression Anxiety Stress Scale; thus total scores range from 0 to 42, with higher scores indicating greater depression, anxiety, and stress.

    Time frame: The Depression Anxiety Stress Scale-21 Items will be completed at immediately before (i.e., baseline) and immediately after the intervention

  2. Preliminary effects of the mindfulness meditation app on depression, as assessed by changes in participants' pre- and post-intervention scores on the Hospital Anxiety and Depression Scale

    The Hospital Anxiety and Depression Scale is a 14-item questionnaire, comprised of two seven-item subscales measuring depression and anxiety. Respondents rate the frequency or severity of anxious and depressive symptoms on a four-point scale. Item ratings range from 0 to 3, with higher ratings reflecting more frequent or severe symptoms. Items from each subscale are summed to calculate total scores for depression and anxiety.

    Time frame: The Hospital Anxiety and Depression Scale will be completed at immediately before (i.e., baseline) and immediately after the intervention

  3. Preliminary effects of the mindfulness meditation app on anxiety, as assessed by changes in participants' pre- and post-intervention scores on the Depression Anxiety Stress Scale-21 Items

    The Depression Anxiety Stress Scale-21 Items is a set of three seven-item self-report scales measuring depression, anxiety, and stress/tension. Respondents use a four-point scale, ranging from 0 to 3, to rate the extent to which symptoms of depression, anxiety, and stress apply to their experiences during the past week (0=did not apply to me at all, 3=applied to me very much, or most of the time). For each scale, ratings for the relevant items are summed, and sums for each scale are multiplied by two to allow for comparison with scores from the original the 42-item version of the Depression Anxiety Stress Scale; thus total scores range from 0 to 42, with higher scores indicating greater depression, anxiety, and stress.

    Time frame: The Depression Anxiety Stress Scale-21 Items will be completed at immediately before (i.e., baseline) and immediately after the intervention

  4. Preliminary effects of the mindfulness meditation app on anxiety, as assessed by changes in participants' pre- and post-intervention scores on the Hospital Anxiety and Depression Scale

    The Hospital Anxiety and Depression Scale is a 14-item questionnaire, comprised of two seven-item subscales measuring depression and anxiety. Respondents rate the frequency or severity of anxious and depressive symptoms on a four-point scale. Item ratings range from 0 to 3, with higher ratings reflecting more frequent or severe symptoms. Items from each subscale are summed to calculate total scores for depression and anxiety.

    Time frame: The Hospital Anxiety and Depression Scale will be completed at immediately before (i.e., baseline) and immediately after the intervention

  5. Preliminary effects of the mindfulness meditation app on stress, as assessed by changes in participants' pre- and post-intervention scores on the Depression Anxiety Stress Scale-21 Items

    The Depression Anxiety Stress Scale-21 Items is a set of three seven-item self-report scales measuring depression, anxiety, and stress/tension. Respondents use a four-point scale, ranging from 0 to 3, to rate the extent to which symptoms of depression, anxiety, and stress apply to their experiences during the past week (0=did not apply to me at all, 3=applied to me very much, or most of the time). For each scale, ratings for the relevant items are summed, and sums for each scale are multiplied by two to allow for comparison with scores from the original the 42-item version of the Depression Anxiety Stress Scale; thus total scores range from 0 to 42, with higher scores indicating greater depression, anxiety, and stress.

    Time frame: The Depression Anxiety Stress Scale-21 Items will be completed at immediately before (i.e., baseline) and immediately after the intervention

07

Study locations

1 site
  • Arizona State University
    Phoenix, Arizona 85004, United States
08

References and documents

Publications

  • Huberty JL, Green J, Puzia ME, Larkey L, Laird B, Vranceanu AM, Vlisides-Henry R, Irwin MR. Testing a mindfulness meditation mobile app for the treatment of sleep-related symptoms in adults with sleep disturbance: A randomized controlled trial. PLoS One. 2021 Jan 7;16(1):e0244717. doi: 10.1371/journal.pone.0244717. eCollection 2021. PubMed 33411779 ↗

Individual participant data

Plan to share: No

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Feb 26, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04045275
Lead sponsor
Arizona State University
Collaborators
Calm.com, Inc.
Responsible party
Jennifer Huberty (Associate Professor, Arizona State University) — Principal investigator
First posted
Aug 5, 2019
Start date
Jun 10, 2019
Primary completion
Jan 1, 2020
Completion
Jan 1, 2020
Last update
Feb 26, 2020

Study contacts

Jennifer Huberty, PhD
principal investigator · Arizona State University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion